Biotime, Inc.
Records under this name other than the patents Biotime, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,745,752 | Methods for telomere length and genomic DNA quality control analysis in pluripotent stem cells Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,961,531 | Compositions and methods for induced tissue regeneration in mammalian species Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 12,421,513 | Compositions and methods for induced tissue regeneration in mammalian species Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 12,492,400 | Compositions and methods for induced tissue regeneration in mammalian species Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 12,404,493 | Methods for the re-derivation of diverse pluripotent stem cell-derived brown fat cells Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,685,386 | Methods and compositions for in vitro and in vivo chondrogenesis Formerly held Lapsed on the fee record Ended Apr 1, 2026 · From the USPTO record | Lapsed on the fee record | Ended Apr 1, 2026 | From the USPTO record |
| US 9,732,128 | Methods of modifying transcriptional regulatory networks in stem cells Formerly held Lapsed on the fee record Ended Aug 15, 2025 · From the USPTO record | Lapsed on the fee record | Ended Aug 15, 2025 | From the USPTO record |
| US 10,920,191 | Methods of screening embryonic progenitor cell lines Formerly held Lapsed on the fee record Ended Feb 16, 2025 · From the USPTO record | Lapsed on the fee record | Ended Feb 16, 2025 | From the USPTO record |
| US 10,865,383 | Methods and formulations for orthopedic cell therapy Formerly held Lapsed on the fee record Ended Dec 15, 2024 · From the USPTO record | Lapsed on the fee record | Ended Dec 15, 2024 | From the USPTO record |
| US 9,175,263 | Methods and compositions for targeting progenitor cell lines Formerly held Lapsed on the fee record Ended Nov 3, 2023 · From the USPTO record | Lapsed on the fee record | Ended Nov 3, 2023 | From the USPTO record |